• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: Trust Family Lindquist L. Susan claimed ownership of 1,184,561 units of Common Stock

    1/4/21 4:39:59 PM ET
    $PTI
    Major Pharmaceuticals
    Health Care
    Get the next $PTI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Susan L. Lindquist Family Trust

    (Last) (First) (Middle)
    C/O NANCY E. DEMPZE HEMENWAY & BARNES,
    LLP, 75 STATE STREET

    (Street)
    BOSTON MA 02109

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    12/22/2020
    3. Issuer Name and Ticker or Trading Symbol
    YUMANITY THERAPEUTICS, INC. [ YMTX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 484,168(1)(2) I See Footnote(3)
    Common Stock 230,170(1)(4) I See Footnote(5)
    Common Stock 241,257(1)(6) I See Footnote(7)
    Common Stock 228,966(1)(8) I See Footnote(9)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrant (Right to Buy) 02/08/2016(10) 08/14/2025 Common Stock 6,038(1)(11) 24.05 I See Footnote(12)
    1. Name and Address of Reporting Person*
    Susan L. Lindquist Family Trust

    (Last) (First) (Middle)
    C/O NANCY E. DEMPZE HEMENWAY & BARNES,
    LLP, 75 STATE STREET

    (Street)
    BOSTON MA 02109

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Susan L. Lindquist Exempt Marital Trust

    (Last) (First) (Middle)
    C/O NANCY E. DEMPZE HEMENWAY & BARNES,
    LLP, 75 STATE STREET

    (Street)
    BOSTON MA 02109

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Susan L. Lindquist Massachusetts Non-Exempt Marital Trust

    (Last) (First) (Middle)
    C/O NANCY E. DEMPZE HEMENWAY & BARNES,
    LLP, 75 STATE STREET

    (Street)
    BOSTON MA 02109

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Susan L. Lindquist Massachusetts Only Marital Trust

    (Last) (First) (Middle)
    C/O NANCY E. DEMPZE HEMENWAY & BARNES,
    LLP, 75 STATE STREET

    (Street)
    BOSTON MA 02109

    (City) (State) (Zip)
    Explanation of Responses:
    1. On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity.
    2. The shares were received in exchange for 2,296,358.67 shares of Yumanity, Inc. common stock in connection with the Merger.
    3. Shares held by Susan L. Lindquist Family Trust. All other reporting persons disclaim beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any.
    4. The shares were received in exchange for 1,091,672 shares of Yumanity, Inc. common stock in connection with the Merger.
    5. Shares held by Susan L. Lindquist Exempt Marital Trust. All other reporting persons disclaim beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any.
    6. The shares were received in exchange for 1,144,257 shares of Yumanity, Inc. common stock in connection with the Merger.
    7. Shares held by Susan L. Lindquist Non-Exempt Marital Trust. All other reporting persons disclaim beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any.
    8. The shares were received in exchange for 1,085,965 shares of Yumanity, Inc. common stock in connection with the Merger.
    9. Shares held by Susan L. Lindquist Massachusetts only Marital Trust. All other reporting persons disclaim beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any.
    10. The warrant is fully vested on the date exercisable.
    11. Received in the Merger in exchange for a warrant to purchase 28,642 shares of Yumanity, Inc. common stock for $5.069 per share.
    12. Warrants held by Susan L. Lindquist Family Trust. All other reporting persons disclaim beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any.
    Remarks:
    The reporting persons may be deemed to be in a "group" as that term is used in Rule 13d-5(b) of the Securities Exchange Act of 1934, as amended. Each of the reporting persons expressly disclaims such group status.
    Susan L. Lindquist Family Trust, By: Nancy E. Dempze, Trustee /s/ Nancy E. Dempze 01/04/2021
    Susan L. Lindquist Exempt Marital Trust, By: Nancy E. Dempze, Trustee /s/ Nancy E. Dempze 01/04/2021
    Susan L. Lindquist Non-Exempt Marital Trust, By: Nancy E. Dempze, Trustee /s/ Nancy E. Dempze 01/04/2021
    Susan L. Lindquist Massachusetts only Marital Trust, By: Nancy E. Dempze, Trustee /s/ Nancy E. Dempze 01/04/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

    Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, today announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors. An experienced biopharma executive, Ms. Chhabra Karson will lend her business, scientific and operational expertise towards helping Harness achieve its next phase of growth as it advances its oligonucleotide-based platform for controlled upregulation of CNS targets and its lead programme in Huntington's disease. Ms. Chhabra Ka

    4/24/24 3:00:00 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio

    BOSTON, Dec. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December 22, 2020 (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated August 22, 2020, as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned s

    12/22/20 10:47:00 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis

    Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis plans to adjourn its special meeting of stockholders to December 22, 2020 BOSTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, and Proteostasis Therapeutics, Inc. (Nasdaq: PTI) today announced that Proteostasis has entered into a definitive agreement for the sale of its Common Stock in a private placement led by Fidelity

    12/15/20 7:00:00 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    $PTI
    Leadership Updates

    Live Leadership Updates

    View All

    Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

    Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, today announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors. An experienced biopharma executive, Ms. Chhabra Karson will lend her business, scientific and operational expertise towards helping Harness achieve its next phase of growth as it advances its oligonucleotide-based platform for controlled upregulation of CNS targets and its lead programme in Huntington's disease. Ms. Chhabra Ka

    4/24/24 3:00:00 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    $PTI
    SEC Filings

    View All

    SEC Form SC 13G filed

    SC 13G - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)

    1/11/21 10:51:55 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    SEC Form 8-K filed

    8-K - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)

    1/11/21 6:30:35 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    SEC Form D filed

    D - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)

    1/6/21 5:28:17 PM ET
    $PTI
    Major Pharmaceuticals
    Health Care